About Us and Our Oncolytic Bacteria

It is known that almost all human diseases, including cancer, occur with changes in microbiome. However, the role of microorganisms, in particular, bacteria, in the development of cancer is still incomprehensible. It was shown that infections caused by different pathogens may in some cases lead to the disappearance of tumor development. The greatest amount of data has been accumulated on the use of Group A streptococci as antitumor bacteria. Herewith, modification of streptococci by genetic engineering could improve the anti-cancer features. Author of the article hypothesize that the opportunistic bacteria might have a biological role of eliminating the cancer cells from the organism.

Keywords

cancer, oncolytic bacteria, Streptococcus pyogenes.

Received

29.09.2018

Publication date

04.10.2018

Number of characters

697

Cite Download pdf To download PDF you should sign in

GOST	Suvorov A. About Us and Our Oncolytic Bacteria // Priroda – 2018. – Issue №8 C. 3-9 [Electronic resource]. URL: http://ras.jes.su/priroda/s0032874x0000478-4-1-en (circulation date: 26.04.2024). DOI: 10.31857/S0032874X0000478-4
MLA	Suvorov, A. "About Us and Our Oncolytic Bacteria." Priroda 8 (2018):3-9. DOI: 10.31857/S0032874X0000478-4
APA	Suvorov A. (2018). About Us and Our Oncolytic Bacteria. Priroda (8), pp.3-9 DOI: 10.31857/S0032874X0000478-4

Размещенный ниже текст является ознакомительной версией и может не соответствовать печатной

Readers community rating: votes 0

1. Tjalsma H., Boleij A., Marchesi J.R., Dutilh B.E. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012; 10(8): 575–582. Doi:10.1038/nrmicro2819.

2. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015; 136(5): E359–E386. Doi:10.1002/ijc.29210.

3. Nair N., Kasai T., Seno M. Bacteria: prospective savior in battle against cancer. Anticancer Res. 2014; 34(11): 6289–6296.

4. Karpisski T.M. Anticancer activity of bacterial proteins and peptides. Pharmaceutics. 2018; 10(2): E54. Doi:10.3390/pharmaceutics10020054.

5. Fiedler T., Straussab M., Hering S. et al. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo. Cancer Biol. Ther. 2015; 16(7): 1047–1055. Doi:10.1080/15384047.2015.1026478.

6. Maletzki C., Rosche Y., Riess C. et al. Deciphering molecular mechanisms of arginine deiminase-based therapy — Comparative response analysis in paired human primary and recurrent glioblastomas. Chem. Biol. Interact. 2017; 278: 179–188. Doi:10.1016/j.cbi.2017.10.007.

7. Krzykawski M.P. Combined bacterial and viral treatment: a novel anticancer strategy. Cent Eur J Immunol. 2015; 40(3): 366–372. Doi:10.5114/ceji.2015.54601.

8. Maletzki C., Klier U., Obst W. et al. Reevaluating the concept of treating experimental tumors with a mixed bacterial vaccine: Coley’s Toxin. Clin. Dev. Immunol. 2012; 2012: 230625. Doi:10.1155/2012/230625.

9. Old L.J., Clark D.A., Benacerraf B. Effect of Bacillus Calmette-Guerin infection on transplanted tumors in the mouse. Nature. 1959; 184: 291–292. Doi:10.1038/184291a0.

10. Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus CalmetteGuerin in the treatment of superficial bladder tumors. J. Urol. 1976; 116(2): 180–183. Doi:10.1016/S0022-5347(17)58737-6.

11. Bonavida B., Katz J., Hoshino T. Mechanism of NK activation by OK432 (Streptococcus pyogenes). I. Spontaneous release of NKCF and augmentation of NKCF production following stimulation with NK target cells. Cell Immunol. 1986; 102(1): 126–135. Doi:10.1016/0008-8749(86)90331-X.

12. Suvorova M. A., Kramskaya T. A., Suvorov A.N., Kiseleva E.P. Inactivation of M111 protein gene modifies Streptococcus pyogenes interactions with mouse macrophages in vitro. Bull. Exp. Biol. Med. 2018; 164(3): 347–350. Doi:10.1007/s10517-018-3987-z.

13. Suvorova M. A., Kramskaya T. A., Duplik N.V. i dr. Vliyanie inaktivatsii gena M-belka na protivoopukholevye svojstva zhivykh Streptococcus pyogenes v ehksperimente. Voprosy onkologii. 2017; 63(5): 803–807. [Suvorova M. A., Kramskaya T. A., Duplik N.V. et al. Influence of inactivation of the Mprotein gene on antitumor activity of live Streptococcus pyogenes in experiment. Problems in oncology. 2017; 63(5): 803–807. (In Russ.).]

14. McMillan D.J., Drize P. A., Vu T. et al. Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. Clin. Microbiol. Infect. 2013; 19(5): E222–E229. Doi:10.1111/1469-0691.12134.